Colossal Biosciences
Beyond Market Intelligence keeps Colossal Biosciences in one place: 2 stories so far. The section currently leads with “AI platform accelerates de-extinction work as new fund backs its adopters” and “Colossal Biosciences eyes new funding to double its de-extinction valuation.”. Colossal's new AI platform aims to speed up de-extinction work, and Peter Diamandis has launched a fund to back startups that adopt it. Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, a move that would double or triple its previous worth. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every Colossal Biosciences story on Beyond Market Intelligence, newest first.

AI platform accelerates de-extinction work as new fund backs its adopters
Colossal's new AI platform aims to speed up de-extinction work, and Peter Diamandis has launched a fund to back startups that adopt it. This pairing of technology and capital could turn ambitious rewilding projects into practical workflows. We see a pattern here: just as Apple TV 4K's Siri AI transforms your viewing experience starting November 13, Colossal is betting AI can reshape what's possible in biology. Explore our coverage of that story for another look at AI-driven transformation.

Colossal Biosciences eyes new funding to double its de-extinction valuation.
Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, a move that would double or triple its previous worth. That kind of ambition signals confidence in a mission that goes far beyond the lab. It's a bold bet on the future of genetic restoration, and one worth watching closely. For more on how AI-native infrastructure is reshaping similar ventures, check out our piece on Nscale's recent funding.